Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA.

Lancet. 2008 Jul 19;372(9634):216-23. doi: 10.1016/S0140-6736(08)61075-2.


Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.

Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M; AN1792 (QS-21)-251 Study Team.

Curr Alzheimer Res. 2009 Apr;6(2):144-51.


Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Boche D, Denham N, Holmes C, Nicoll JA.

Acta Neuropathol. 2010 Sep;120(3):369-84. doi: 10.1007/s00401-010-0719-5. Epub 2010 Jul 15. Review.


Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, Frosch MP, Hyman BT.

Brain. 2010 May;133(Pt 5):1312-27. doi: 10.1093/brain/awq056. Epub 2010 Mar 31.


Microglial alterations in human Alzheimer's disease following Aβ42 immunization.

Zotova E, Holmes C, Johnston D, Neal JW, Nicoll JA, Boche D.

Neuropathol Appl Neurobiol. 2011 Aug;37(5):513-24. doi: 10.1111/j.1365-2990.2010.01156.x.


Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0. Epub 2012 Jun 6.


Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease.

Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F, Pickering RM, Nicoll JA, Holmes C, Hugon J, Boche D.

J Pathol. 2015 Apr;235(5):721-30. doi: 10.1002/path.4491. Epub 2015 Jan 7.


Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.

Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JA.

Acta Neuropathol. 2010 Jul;120(1):13-20. doi: 10.1007/s00401-010-0705-y. Epub 2010 Jun 9.


Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team.

Neurology. 2005 May 10;64(9):1553-62.


Alternative Abeta immunotherapy approaches for Alzheimer's disease.

Town T.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):114-27. Review.


Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA.

Brain. 2008 Dec;131(Pt 12):3299-310. doi: 10.1093/brain/awn261. Epub 2008 Oct 25.


Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study.

Neurology. 2005 May 10;64(9):1563-72.


Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.

Wang CM, Devries S, Camboni M, Glass M, Martin PT.

Neurobiol Dis. 2010 Sep;39(3):409-22. doi: 10.1016/j.nbd.2010.05.013. Epub 2010 May 20.


Brain amyloid-β oligomers in ageing and Alzheimer's disease.

Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH.

Brain. 2013 May;136(Pt 5):1383-98. doi: 10.1093/brain/awt062. Epub 2013 Apr 9.


A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.

Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML.

Neuron. 2012 Dec 6;76(5):908-20. doi: 10.1016/j.neuron.2012.10.029.


Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.


Amyloid-beta immunotherapy for Alzheimer's disease.

Fu HJ, Liu B, Frost JL, Lemere CA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. Review.


T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease.

Fisher Y, Nemirovsky A, Baron R, Monsonego A.

PLoS One. 2010 May 26;5(5):e10830. doi: 10.1371/journal.pone.0010830.


Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice.

Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH.

J Neuroinflammation. 2008 Sep 29;5:42. doi: 10.1186/1742-2094-5-42.

Items per page

Supplemental Content

Support Center